Lake Street analyst Thomas Flaten raised the firm’s price target on Checkpoint Therapeutics (CKPT) to $7 from $4 and keeps a Buy rating on the shares after the company announced FDA approval of Unloxcyt for advanced cutaneous squamous cell carcinoma on Friday. The firm expects commercialization, likely in the second half of 2025, will be “via acquisition/partnership,” the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CKPT: